Finorify

ONC

BeiGene Ltd

$366.73-1.55%

Price

ONC daily closing price
Market cap
$40.92 billion
P/E (TTM)
64.11
EV/EBITDA
33.96
52W range
$260.27 – $377.47
Volume
341.6K
Sector
Healthcare

BeiGene Ltd (ONC) last closed at $366.73, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for ONC, covered for search and blurred for visitors.

Performance

  • 1D+0.51%
  • 5D+9.95%
  • 1M+4.99%
  • 3M+18.27%
  • 6M+23.70%
  • 1Y+21.30%
  • 5Y+8.43%

Financials

ONC revenueQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Over the latest four reported periods ending June 30, 2026, BeiGene Ltd reported revenue of $6.13 billion.

The prior window totaled $4.56 billion, so the latest window is higher than that stretch.

Operating cash flow in the latest window was $1.48 billion.

Free cash flow in the latest window was $1.33 billion.

These amounts are taken from BeiGene Ltd's SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE 4.6% (22 of 100). Leverage: D/E 0.15× (94 of 100). Cash generation: FCF margin 21.7% (43 of 100). Net margin: 13.9% (35 of 100). Liquidity: Current 3.40× (100 of 100).

Finorify's notes from those filings, written August 30, 2026: Established Global Commercial Oncology Franchise. The company possesses validated, commercialized cancer therapies with broad regulatory approvals across key global markets including the United States, Europe, and Asia. Its established commercial infrastructure and market penetration in hematology and solid tumors provide a diversified, growing revenue foundation that funds ongoing clinical programs. Integrated, High-Efficiency In-House Clinical Development Engine. Operating a large, internalized clinical operations team allows the company to design and execute global clinical trials with greater speed and cost efficiency than peers reliant primarily on contract research organizations (CROs). This operational model accelerates trial enrollment, shortens development timelines, and optimizes R&D capital expenditure. Broad Multi-Modality Pipeline and R&D Capabilities. The company maintains proprietary discovery platforms spanning small molecules, antibody-drug conjugates (ADCs), bispecific antibodies, and targeted protein degraders. This multifaceted R&D architecture supports continuous pipeline replenishment and facilitates internal combination therapies, creating strong defensive moats against single-asset obsolescence. Intense Market and Mechanism Competition. The oncology landscape is heavily crowded, particularly within established classes like BTK inhibitors and PD-1/PD-L1 checkpoint inhibitors. Competitors, including major global pharmaceutical companies with deep commercial resources, continually advance alternative standard-of-care treatments and novel mechanisms that could erode market share and pricing power. Clinical Trial Attrition and Regulatory Hurdles. The company's long-term enterprise value depends on successfully expanding drug labels and commercializing early-to-late-stage pipeline assets. Pipeline candidates face substantial risks of clinical failure, adverse safety profiles, trial delays, or regulatory rejection across key health authorities such as the FDA, EMA, and NMPA. Geopolitical, Supply Chain, and Cross-Border Operational Exposure. With extensive cross-border operations spanning the United States, Europe, and Asia, the company is vulnerable to geopolitical frictions, trade restrictions, export controls, and divergent international regulatory standards. These dynamics could disrupt global clinical trials, cross-border supply chains, and international manufacturing integrity.

Cash Flow

ONC free cash flowQ3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Margins

ONC operating margin

Valuation

P/E (TTM)
64.11
P/S (TTM)
6.68
EV/EBITDA
33.96

Insights

Advantage

Established Global Commercial Oncology Franchise

The company possesses validated, commercialized cancer therapies with broad regulatory approvals across key global markets including the United States, Europe, and Asia. Its established commercial infrastructure and market penetration in hematology and solid tumors provide a diversified, growing revenue foundation that funds ongoing clinical programs.

Advantage

Integrated, High-Efficiency In-House Clinical Development Engine

Operating a large, internalized clinical operations team allows the company to design and execute global clinical trials with greater speed and cost efficiency than peers reliant primarily on contract research organizations (CROs). This operational model accelerates trial enrollment, shortens development timelines, and optimizes R&D capital expenditure.

Advantage

Broad Multi-Modality Pipeline and R&D Capabilities

The company maintains proprietary discovery platforms spanning small molecules, antibody-drug conjugates (ADCs), bispecific antibodies, and targeted protein degraders. This multifaceted R&D architecture supports continuous pipeline replenishment and facilitates internal combination therapies, creating strong defensive moats against single-asset obsolescence.

Risk

Intense Market and Mechanism Competition

The oncology landscape is heavily crowded, particularly within established classes like BTK inhibitors and PD-1/PD-L1 checkpoint inhibitors. Competitors, including major global pharmaceutical companies with deep commercial resources, continually advance alternative standard-of-care treatments and novel mechanisms that could erode market share and pricing power.

Risk

Clinical Trial Attrition and Regulatory Hurdles

The company's long-term enterprise value depends on successfully expanding drug labels and commercializing early-to-late-stage pipeline assets. Pipeline candidates face substantial risks of clinical failure, adverse safety profiles, trial delays, or regulatory rejection across key health authorities such as the FDA, EMA, and NMPA.

Risk

Geopolitical, Supply Chain, and Cross-Border Operational Exposure

With extensive cross-border operations spanning the United States, Europe, and Asia, the company is vulnerable to geopolitical frictions, trade restrictions, export controls, and divergent international regulatory standards. These dynamics could disrupt global clinical trials, cross-border supply chains, and international manufacturing integrity.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open ONC in Finorify